Gilroy D - Search Results

1

Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A₄ Mimetics (QNX-sLXms).

de Gaetano M, Tighe C, Gahan K, Zanetti A, Chen J, Newson J, Cacace A, Marai M, Gaffney A, Brennan E, Kantharidis P, Cooper ME, Leroy X, Perretti M, Gilroy D, Godson C, Guiry PJ. de Gaetano M, et al. Among authors: gilroy d. J Med Chem. 2021 Jul 8;64(13):9193-9216. doi: 10.1021/acs.jmedchem.1c00403. Epub 2021 Jun 17. J Med Chem. 2021. PMID: 34138563 Free PMC article.

2

Aspirin and steroids: new mechanistic findings and avenues for drug discovery.

Gilroy DW, Perretti M. Gilroy DW, et al. Curr Opin Pharmacol. 2005 Aug;5(4):405-11. doi: 10.1016/j.coph.2005.02.006. Curr Opin Pharmacol. 2005. PMID: 15955733 Review.

3

Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways.

Morris T, Stables M, Colville-Nash P, Newson J, Bellingan G, de Souza PM, Gilroy DW. Morris T, et al. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8842-7. doi: 10.1073/pnas.1000373107. Epub 2010 Apr 26. Proc Natl Acad Sci U S A. 2010. PMID: 20421472 Free PMC article. Clinical Trial.

4

Effects of low-dose aspirin on acute inflammatory responses in humans.

Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G, Gilroy DW. Morris T, et al. J Immunol. 2009 Aug 1;183(3):2089-96. doi: 10.4049/jimmunol.0900477. Epub 2009 Jul 13. J Immunol. 2009. PMID: 19597002 Clinical Trial.

5

In vivo models to study cyclooxygenase products in health and disease: Introduction to Part III.

Gilroy DW, Stables M, Newson J. Gilroy DW, et al. Methods Mol Biol. 2010;644:181-8. doi: 10.1007/978-1-59745-364-6_15. Methods Mol Biol. 2010. PMID: 20645174

6

Inflammatory resolution: new opportunities for drug discovery.

Gilroy DW, Lawrence T, Perretti M, Rossi AG. Gilroy DW, et al. Nat Rev Drug Discov. 2004 May;3(5):401-16. doi: 10.1038/nrd1383. Nat Rev Drug Discov. 2004. PMID: 15136788 Review. No abstract available.

7

Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor.

Blackwell NM, Sembi P, Newson JS, Lawrence T, Gilroy DW, Kabouridis PS. Blackwell NM, et al. Arthritis Rheum. 2004 Aug;50(8):2675-84. doi: 10.1002/art.20467. Arthritis Rheum. 2004. PMID: 15334484 Free PMC article.

8

Targeting lipoxygenases with care.

de Souza PM, Newson J, Gilroy DW. de Souza PM, et al. Chem Biol. 2006 Nov;13(11):1121-2. doi: 10.1016/j.chembiol.2006.11.002. Chem Biol. 2006. PMID: 17113992

9

A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties.

Navarro-Xavier RA, Newson J, Silveira VL, Farrow SN, Gilroy DW, Bystrom J. Navarro-Xavier RA, et al. J Immunol. 2010 Feb 1;184(3):1516-25. doi: 10.4049/jimmunol.0902866. Epub 2009 Dec 23. J Immunol. 2010. PMID: 20032295

10

Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria.

Stables MJ, Newson J, Ayoub SS, Brown J, Hyams CJ, Gilroy DW. Stables MJ, et al. Blood. 2010 Oct 21;116(16):2950-9. doi: 10.1182/blood-2010-05-284844. Epub 2010 Jul 6. Blood. 2010. PMID: 20606163 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

180 results

Search Page